journal article·2014-10-27Open access

Replacing the Transfusion of 1–2 Units of Blood with Plasma Expanders that Increase Oxygen Delivery Capacity: Evidence from Experimental Studies

Amy Tsai, Beatriz Salazar Vázquez, Pedro Cabrales, Erik Kistler, Daniel Tartakovsky, Shankar Subramaniam, Seetharama Acharya, Marcos Intaglietta

Abstract

At least a third of the blood supply in the world is used to transfuse 1–2 units of packed red blood cells for each intervention and most clinical trials of blood substitutes have been carried out at this level of oxygen carrying capacity (OCC) restoration. However, the increase of oxygenation achieved is marginal or none at all for molecular hemoglobin (Hb) products, due to their lingering vasoactivity. This has provided the impetus for the development of “oxygen therapeutics” using Hb-based molecules that have high oxygen affinity and target delivery of oxygen to anoxic areas. However it is still unclear how these oxygen carriers counteract or mitigate the functional effects of anemia due to obstruction, vasoconstriction and under-perfusion. Indeed, they are administered as a low dosage/low volume therapeutic Hb (subsequently further diluted in the circulatory pool) and hence induce extremely small OCC changes. Hyperviscous plasma expanders provide an alternative to oxygen therapeutics by increasing the oxygen delivery capacity (ODC); in anemia they induce supra-perfusion and increase tissue perfusion (flow) by as much as 50%. Polyethylene glycol conjugate albumin (PEG-Alb) accomplishes this by enhancing the shear thinning behavior of diluted blood, which increases microvascular endothelial shear stress, causes vasodilation and lowering peripheral vascular resistance thus facilitating cardiac function. Induction of supra-perfusion takes advantage of the fact that ODC is the product of OCC and blood flow and hence can be maintained by increasing either or both. Animal studies suggest that this approach may save a considerable fraction of the blood supply. It has an additional benefit of enhancing tissue clearance of toxic metabolites.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Hemoglobin structure and function · Heme Oxygenase-1 and Carbon Monoxide · Erythrocyte Function and Pathophysiology

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Bioengineering, University of California, San Diego (UCSD), La Jolla, CA 92093, USA

Department of Experimental Medicine, School of Medicine, Universidad Nacional Autónoma de México (UNAM), México, D.F. 06726, Mexico

Department of Odontology, Universidad Juárez del Estado de Durango (UJED), Durango, Dgo. 34000, Mexico

Department of Anesthesiology & Critical Care, VA San Diego Healthcare System, La Jolla, CA 92161, USA

Department of Mechanical and Aerospace Engineering, University of California, San Diego (UCSD), La Jolla, CA 92093, USA

Departments of Cellular and Molecular Medicine and Chemistry and Biochemistry, University of California, San Diego (UCSD), La Jolla, CA 92093, USA

Department of Hematology and Medicine, Albert Einstein College of Medicine (AECOM), Bronx, NY 10461, USA

Funding

NIH · USAMRAA · VHA

References (59)

Show source-provided references
1. Current risks of transfusion-transmitted agents: A review10.5858/2007-131-702-CROTAA ↗
2. Blood loss in the minimally invasive posterior approach to total hip arthroplasty: A comparative study10.1590/S1807-59322008000300011 ↗
3. Adverse blood transfusion outcomes: Establishing causation10.1016/j.tmrv.2010.11.001 ↗
4. Lynch, C.B., Keith, L.G., Lalonde, A.B., and Karoshi, M. (2006). A Comprehensive Textbook of Postpartum Hemorrhage, Sapiens Publishing.
5. Transfusion-related acute lung injury: Incidence and risk factors10.1182/blood-2011-08-370932 ↗
6. What is really dangerous: Anaemia or transfusion?10.1093/bja/aer350 ↗
7. Effect of blood transfusion on long-term survival after cardiac operation10.1016/S0003-4975(02)03766-9 ↗
8. Transfusion in coronary artery bypass grafting is associated with reduced long-term survival10.1016/j.athoracsur.2005.12.037 ↗
9. Evaluation of single unit red cell transfusions given to adults during surgery10.4103/0973-6247.28067 ↗
10. A survey of the demographics of blood use10.1111/j.1365-3148.2006.00709.x ↗
11. Blood use in elective surgery: The Austrian benchmark study10.1111/j.1537-2995.2007.01286.x ↗
12. A retrospective study evaluating single-unit red blood cell transfusions in reducing allogeneic blood exposure10.1111/j.0958-7578.2005.00592.x ↗
13. Significant reduction of red blood cell transfusion requirements by changing from a double-unit to a single-unit transfusion policy in patients receiving intensive chemotherapy or stem cell transplantation10.3324/haematol.2011.047035 ↗
14. Transfusion of 1 and 2 units of red blood cells is associated with increased morbidity and mortality10.1016/j.athoracsur.2013.07.020 ↗
15. Factors influencing the individual effects of blood transfusions on oxygen delivery and oxygen consumption10.1097/00003246-199910000-00021 ↗
17. MP4, a new nonvasoactive PEG-Hb conjugate10.1046/j.1537-2995.2003.00341.x ↗
18. Artificial oxygen carrier with pharmacologic actions of adenosine-5′-triphosphate, adenosine, and reduced glutathione formulated to treat an array of medical conditions10.1111/aor.12337 ↗
19. A hemoglobin-based multifunctional therapeutic: Polynitroxylated pegylated hemoglobin10.1111/j.1525-1594.2011.01307.x ↗
20. CO-MP4, a polyethylene glycol-conjugated haemoglobin derivative and carbon monoxide carrier that reduces myocardial infarct size in rats10.1038/bjp.2008.219 ↗
21. Microvascular and systemic effects following top load administration of saturated carbon monoxide-saline solution
22. Microvascular and tissue oxygen distribution10.1016/S0008-6363(96)00110-1 ↗
23. Oxygen therapeutics: Can we tame haemoglobin?10.1038/nrd1307 ↗
24. Setbacks in blood substitutes research and development: A biochemical perspective10.1016/j.cll.2010.02.009 ↗
25. Can the effects of vasoactivity of molecular hemoglobin-based plasma expanders be ignored?10.1097/01.CCM.0000216188.79290.20 ↗
27. Oxygen supply to the tissues during limited normovolemic hemodilution10.1007/BF01851543 ↗
28. Cardiovascular benefits in moderate increases of blood and plasma viscosity surpass those associated with lowering viscosity: Experimental and clinical evidence10.3233/CH-2010-1261 ↗
29. Blood viscosity: A factor in tissue survival?10.1097/01.CCM.0000170177.64555.DB ↗
30. Plasma viscosity regulates capillary perfusion during extreme hemodilution in hamster skinfold model
31. High viscosity plasma expanders: Volume restitution fluids for lowering the transfusion trigger
32. Does colloid-induced plasma hyperviscosity in haemodilution jeopardize perfusion and oxygenation of vital organs?10.1111/j.1399-6576.1995.tb04050.x ↗
33. Lack of dependence of cerebral blood flow on blood viscosity after blood exchange with a Newtonian O2 carrier10.1038/jcbfm.1994.109 ↗
34. Gender difference in rheologic properties of blood and risk of cardiovascular diseases
35. Vascular wall shear stress: Basic principles and methods
36. Elevated plasma viscosity in extreme hemodilution increases perivascular nitric oxide concentration and microvascular perfusion10.1152/ajpheart.00998.2004 ↗
37. Alginate plasma expander maintains perfusion and plasma viscosity during extreme hemodilution10.1152/ajpheart.00911.2004 ↗
38. Plasma viscosity regulates systemic and microvascular perfusion during acute extreme anemic conditions10.1152/ajpheart.00394.2006 ↗
39. Increase plasma viscosity sustains microcirculation after resuscitation from hemorrhagic shock and continuous bleeding
40. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol10.1016/S0021-9258(17)40291-2 ↗
41. Extreme hemodilution with PEG-hemoglobin vs. PEG-albumin10.1152/ajpheart.00225.2005 ↗
42. PEG-albumin supra plasma expansion is due to increased vessel wall shear stress induced by blood viscosity shear thinning10.1152/ajpheart.01090.2011 ↗
43. Plasma viscosity: A forgotten variable10.3233/CH-2008-1088 ↗
44. Microvascular effects following treatment with polyethylene glycol-albumin in lipopolysaccharide-induced endotoxemia10.1097/01.CCM.0000190623.97200.82 ↗
45. Systemic and subcutaneous microvascular Po2 dissociation during 4-h hemorrhagic shock in conscious hamsters10.1152/ajpheart.1996.270.3.H827 ↗
46. Endogenous nitric oxide in the control of skeletal muscle oxygen extraction during exercise10.1046/j.1365-201x.2000.00719.x ↗
47. Nitric oxide-mediated mitochondrial damage in the brain: Mechanisms and implications for neurodegenerative diseases10.1046/j.1471-4159.1997.68062227.x ↗
48. Model analysis of the enhancement of tissue oxygenation by hemodilution due to increased microvascular flow velocity10.1016/0026-2862(87)90062-8 ↗
49. Whitaker lecture 1996: Microcirculation, biomedical engineering and artificial blood10.1007/BF02684838 ↗
50. Technical report: A new chamber technique for microvascular studies in unanaesthetized hamsters10.1007/BF01851841 ↗
51. A transparent access chamber for the rat dorsal skin fold10.1016/0026-2862(79)90039-6 ↗
52. Microvascular pressure and functional capillary density in extreme hemodilution with low and high plasma viscosity expanders10.1152/ajpheart.01039.2003 ↗
53. Role of endothelial nitric oxide in microvascular oxygen delivery and consumption10.1016/j.freeradbiomed.2005.06.019 ↗
54. Hemorrhagic shock resuscitation with carbon monoxide saturated blood10.1016/j.resuscitation.2006.06.021 ↗
55. Is resuscitation from hemorrhagic shock limited by blood oxygen-carrying capacity or blood viscosity?10.1097/01.shk.0000239782.71516.ba ↗
56. Resuscitation from hemorrhagic shock with MalPEG-albumin: Comparison with MalPEG-hemoglobin10.1097/01.shk.0000135253.14076.d9 ↗
57. Cardiac systolic function recovery after hemorrhage determines survivability during shock
58. Effects of plasma viscosity modulation on cardiac function during moderate hemodilution10.4103/0973-6247.67034 ↗
59. Effects on cardiac function of a novel low viscosity plasma expander based on polyethylene glycol conjugated albumin